Thomson Medical Group Limited has announced a 6.4% increase in revenue for the financial year ending 30 June 2026, reaching S$420.1m. The Group’s adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose by 9.9% to S$82.5m, whilst net loss after tax decreased by 40.8% to S$27.8m, compared to S$47m the previous year.
The revenue boost was attributed to higher revenue intensity and improved pricing in Singapore, contributions from the Oncology Centre in Malaysia, and increased patient volumes in Vietnam. However, the Vietnamese Dong’s unfavourable exchange rate partially offset Vietnam’s gains. Malaysia’s performance was notably strong, driven by the expansion of oncology and specialist services.
Group CEO Melvin Heng stated, “We entered FY2026 focused on translating the investments we have made into stronger operating performance. The full-year results show that we are making progress, with revenue growing across the Group and adjusted EBITDA improving faster than the top line.”
The Group’s EBITDA increased by 23.2% to S$67.3m and operating cash flows rose 17.4% to S$71m. The Group also benefited from reduced financing costs, with net finance costs falling 15.4% to S$47.4m due to lower interest rates.
Looking ahead, Thomson Medical aims to enhance execution and operating leverage across its regional portfolio, focusing on expanding specialist services in Singapore, Malaysia, and Vietnam. The Group plans to maintain a disciplined investment approach to achieve sustainable long-term earnings.
